Pulmonx (LUNG) Net Income towards Common Stockholders (2019 - 2025)
Pulmonx (LUNG) posted quarterly Net Income towards Common Stockholders of -$14.0 million for Q3 2025, up 1.38% year-over-year from -$13.8 million in Q3 2024, and up 8.15% quarter-over-quarter from -$15.2 million in Q2 2025.
Pulmonx (LUNG) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends
Pulmonx (LUNG) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$14.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Net Income towards Common Stockholders rose 1.38% year-over-year to -$14.0 million; the TTM figure through Dec 2025 stood at -$43.6 million (up 22.69% YoY), while the FY2024 annual figure was -$56.4 million, up 7.31% from the prior year.
- Net Income towards Common Stockholders improved to -$14.0 million in Q3 2025 per LUNG's latest filing, from -$15.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$10.2 million in Q3 2021 and bottomed at -$16.2 million in Q2 2023.
- Historically, Net Income towards Common Stockholders has averaged -$14.1 million across 5 years, with a median of -$14.2 million in 2022.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 163.76% — and 2024, when it advanced 13.22%.
- Pulmonx's Net Income towards Common Stockholders stood at -$13.0 million in 2021, then dropped by 9.89% to -$14.3 million in 2022, then gained by 2.77% to -$13.9 million in 2023, then advanced by 5.41% to -$13.1 million in 2024, then retreated by 6.24% to -$14.0 million in 2025.
- Business Quant data shows LUNG's Net Income towards Common Stockholders at -$14.0 million in Q3 2025, -$15.2 million in Q2 2025, and -$14.4 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Pulmonx | 93.95 Mn | 24.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -13.96 Mn |
| Jun 30, 2025 | -15.20 Mn |
| Mar 31, 2025 | -14.45 Mn |
| Dec 31, 2024 | -13.14 Mn |
| Sep 30, 2024 | -14.15 Mn |
| Jun 30, 2024 | -15.34 Mn |
| Mar 31, 2024 | -13.76 Mn |
| Dec 31, 2023 | -13.89 Mn |
| Sep 30, 2023 | -14.94 Mn |
| Jun 30, 2023 | -16.20 Mn |
| Mar 31, 2023 | -15.86 Mn |
| Dec 31, 2022 | -14.28 Mn |
| Sep 30, 2022 | -14.17 Mn |
| Jun 30, 2022 | -14.64 Mn |
| Mar 31, 2022 | -15.86 Mn |
| Dec 31, 2021 | -13.00 Mn |
| Sep 30, 2021 | -10.18 Mn |
| Jun 30, 2021 | -12.98 Mn |
| Mar 31, 2021 | -12.55 Mn |
| Dec 31, 2020 | -9.29 Mn |